Maryland Woman Gets Gene Therapy to Cure Sickle Cell Disease

Jessica Ceja spent most of her 41 years managing the excruciating pain of sickle cell disease, missing birthday parties, school events, and precious moments with her three children. On April 27, she received an infusion of her own genetically modified stem cells at the University of Maryland Medical Center, becoming the first adult sickle cell patient in Maryland to get this potentially life-changing treatment.

Ceja was diagnosed at age 2 with the inherited blood disorder that affects 100,000 Americans and millions worldwide. The disease causes red blood cells to become crescent-shaped, blocking blood flow and triggering severe pain episodes that sent her to the hospital again and again.

For years, her only options were pain medications, frequent blood transfusions, and a drug called hydroxyurea to reduce symptoms. As an only child, she had no family donor available for a traditional stem cell transplant, which had been the only known cure.

The gene therapy, called Lyfgenia, works by collecting a patient's own stem cells and genetically modifying them in a lab to produce healthy hemoglobin. After high-dose chemotherapy clears diseased cells from the bone marrow, the modified cells are returned to the patient's body.

The FDA approved the treatment in December 2023 for patients 12 and older with severe sickle cell disease. Clinical trials showed that 88 to 93 percent of patients who received gene therapy were free from pain crises after treatment.

More than 5,000 Marylanders live with sickle cell disease, and the state ranks fifth nationally in cases. The disease most commonly affects people of African descent but also occurs in Hispanic and Middle Eastern populations.

Dr. Jean Yared and Dr. Jennie Law led the development of the sickle cell gene therapy program at the University of Maryland, building the infrastructure needed to safely deliver this complex treatment. The program builds on the hospital's experience with other cellular therapies and expands into curative gene-based treatments.

Why This Inspires

Ceja's words capture what this breakthrough means beyond medical achievement. "Not to have so many hospital visits, not to miss out on family events, not to miss out on my children's activities, their lives, and to be able to plan ahead and participate," she said. She's talking about being present for her kids, ages 5 to 18, and finally planning a future without constant pain.

Major insurers and Medicaid now cover the therapy in many states, including Maryland, making it accessible to patients who need it most. The University of Maryland team's goal is to expand access across the region, giving more patients a realistic shot at a cure.

For someone who's lived with limited options since childhood, the possibility feels almost unimaginable but beautifully real.